Should You Buy Neogen Corp (NEOG) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Sell
Latest Price
10.210
1 Day change
-1.35%
52 Week Range
11.960
Analysis Updated At
2026/01/30
NEOG is not a good buy right now. Pre-market strength (10.28) is running into near-term resistance (~10.31) with momentum looking stretched (RSI 72.55) while a fresh product recall creates headline/event risk. With no Intellectia buy signals today and pattern-based odds pointing to near-term drift lower, the risk/reward favors avoiding new entries (or trimming/exiting if already long).
Technical Analysis
Trend is bullish on moving averages (SMA_5 > SMA_20 > SMA_200), but the setup looks extended short-term. RSI_6 at 72.55 signals the stock is near overbought levels, and MACD is positive (histogram 0.0392) but contracting, suggesting upside momentum is weakening. Price is also close to resistance R1 ~10.312 (pre-market 10.28), so upside looks capped unless it cleanly breaks above ~10.31; key downside levels are pivot 9.738 then S1 9.163. Pattern-based forward view provided is bearish-leaning: ~70% chance of -1.06% next day, -2.26% next week, -3.79% next month.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Options positioning is call-skewed: open interest put/call at 0.37 indicates more call OI than puts (bullish tilt). Volume put/call at 0.01 is extremely call-dominant, but note total volume is low (173 contracts; puts only 1), so sentiment read may be noisy. Implied vol (30D ~66.27) is elevated and above historical volatility (~71.95 is higher, but both are high), consistent with event/headline uncertainty; IV percentile ~58.8 suggests it’s not at extremes but still elevated.
Technical Summary
Sell
3
Buy
9
Positive Catalysts
after a revenue/EBITDA beat and raised guidance. Hedge funds are reportedly buying aggressively (buying amount up ~999% QoQ), which can provide support. Gross margin improved sharply (47.48%, +22.37% YoY), suggesting cost actions/mix are helping.
Neutral/Negative Catalysts
on a nationwide/voluntary recall of HYCOAT Hyaluronate Sodium Sterile Solution due to microbial contamination, which can pressure sentiment, create costs, and raise scrutiny. Technicals are stretched (RSI >
and MACD is contracting near resistance (~10.31). Forward pattern probabilities provided indicate a bearish drift over 1D/1W/1M. No recent insider buying trend (insiders neutral). No recent politician/congress trades reported (no congress data available).
Financial Performance
Latest quarter: 2026/Q2. Revenue declined to $224.691M (-2.84% YoY), and profitability worsened with net income -$15.924M (down -96.51% YoY) and EPS -0.07 (down -96.67% YoY). The bright spot is gross margin rising to 47.48% (+22.37% YoY), implying operational improvements, but top-line contraction and deep losses make the equity more sensitive to negative surprises (like recalls).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend is improving: ratings moved more constructive (upgrade to Outperform at CJS) and Guggenheim maintained Buy while lifting its price target to $12 from $8. Wall Street pros: guidance lift, signs cost actions are working, and margin improvement. Cons: revenue still down YoY, earnings still meaningfully negative, and recall-driven uncertainty can derail the near-term narrative.
Wall Street analysts forecast NEOG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast NEOG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 10.350
Low
6.5
Averages
8.17
High
10
Current: 10.350
Low
6.5
Averages
8.17
High
10
Guggenheim
Buy
maintain
$8 -> $12
AI Analysis
2026-01-09
Reason
Guggenheim
Price Target
$8 -> $12
AI Analysis
2026-01-09
maintain
Buy
Reason
Guggenheim raised the firm's price target on Neogen to $12 from $8 and keeps a Buy rating on the shares after the company beat revenue and EBITDA expectations and raised guidance. While stating that one quarter "does not make a trend," the firm adds that the portfolio performed well and cost actions "clearly are starting to take hold."
CJS Securities
Robert Labick
Market Perform -> Outperform
upgrade
$10
2025-12-10
Reason
CJS Securities
Robert Labick
Price Target
$10
2025-12-10
upgrade
Market Perform -> Outperform
Reason
CJS Securities analyst Robert Labick upgraded Neogen to Outperform from Market Perform with a $10 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NEOG
